OncoTac will provide Scott & White with quantities of anticancer drugs extracted from a group of substances called peptidotoxins. When developed using the company’s proprietary OncoMpact technology, these drugs selectively seek out cancer cells and attach to the cell’s surface.
Once attached, the agent activates a toxic reaction inside the cancer cell, stopping vital cell processes. From recent work it appears these drugs may be very effective in fighting the cancer while minimizing side effects to the patient.
“OncoTac provides the compounds our R&D work needs to bring cancer treatments from bench to bedside in a shorter period of time,” said Dr Frankel. “It is a very specialized area of pharmaceutical development, with quality and safety carrying a very high premium.”